0.04Open0.04Pre Close0 Volume15 Open Interest110.00Strike Price0.00Turnover239.86%IV332.72%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier20DDays to Expiry0.04Extrinsic Value100Contract SizeAmericanOptions Type0.0098Delta0.0018Gamma635.75Leverage Ratio-0.0087Theta0.0001Rho6.22Eff Leverage0.0016Vega
Neurogene Stock Discussion
This Will continue to drive downward. And after you finally sell your position for a loss, they will buy back. Follow the money
📊⚡️📊
NEWS
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome will be ...
No comment yet